NanoBio Corp. raises $12M in Series B

February 19, 2009: NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, has received $12 million in series B equity financing with Perseus LLC and other existing investors, the company announced in a news release.

More than $80 million in funding has been directed toward the development of the company’s NanoStat technology platform, according to the Ann Arbor, Mich., based firm.

The Series B funding will be used by the company to complete a phase 1 study investigating a novel topical treatment for acne, preclinical studies on a nebulized therapy for cystic fibrosis, and a phase 1 study for an intranasal seasonal influenza vaccine.

This funding follows several recent product announcements by NanoBio, including:

  • Phase 2b data indicating that the company’s topical herpes labialis product speeds healing as effectively as the leading oral systemic drugs but without safety or toxicity concerns
  • Preclinical data demonstrating that the company’s novel nanoemulsion technology kills highly resistant bacteria found in patients with cystic fibrosis
  • Preclinical data indicating that a single administration of NanoBio’s novel intranasal influenza vaccine elicits immune responses in ferrets more than 20 times higher than those generated by two injections of currently approved vaccines

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.